Drug Trial Radar · NCT07239674
Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC
Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
646
Planned (sponsor's estimate)
Start
Nov 30, 2025
Primary completion
Nov 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- West China Tianfu Hospital; Shang Jin Hospital of West China Hospital,Sichuan University; Sichuan Academy of Medical Sciences; First Affiliated Hospital of Guangxi Medical University; First Affiliated Hospital of Kunming Medical University; Xijing Hospital of Airforce Medical University; Sir Run Run Shaw Hospital; First Affiliated Hospital of Chongqing Medical University; The Affiliated Hospital Of Guizhou Medical University; The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Lanzhou University; Qinghai Province Fifth People's Hospital; The Affiliated Hospital of Inner Mongolia Medical University; The First Affiliated Hospital of Shanxi Medical University; General Hospital of Ningxia Medical University; Yantai Yuhuangding Hospital; Sun Yat-Sen University Cancer Center; Zhongnan Hospital
- First posted
- Nov 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The global incidence of Differentiated Thyroid Cancer (DTC) is rising. While surgery followed by TSH suppression is the standard of care, achieving target TSH levels with levothyroxine (L-T4) monotherapy remains challenging, with only 25-70% of intermediate/high-risk patients attaining it within 6-8 months. This therapeutic dilemma stems from three key issues: impaired T4-to-T3 conversion due to DIO2 polymorphisms, the non-physiological hormone ratio of T4 monotherapy, and L-T4's narrow therapeutic window. This often results in an "under- versus over-suppression" paradox, increasing risks of recurrence, atrial fibrillation, and osteoporosis. Combining L-T4 with desiccated thyroid extract (DTE; T4:T3 ≈ 4:1) may overcome these limitations by bypassing DIO2 defects and providing a more physiological hormone profile, thereby potentially improving TSH control while mitigating side effects. Supported by the 2023 Chinese guidelines and our promising pilot data (82% cumulative target attainment at a median of 1.4 months), we propose a two-stage national study: a multicenter cohort study followed by a randomized trial, to generate high-level evidence for this combination therapy in high-risk DTC.
Conditions
- Intermediate-to-High Risk Differentiated Thyroid Cancer
Interventions
desiccated thyroid extract (DTE)+levothyroxine (L-T4)Drug
Desiccated thyroid extract (DTE) is a dry preparation obtained from animal thyroid glands that contains both thyroxine (T4) and triiodothyronine (T3) in an approximately 4:1 ratio, closely matching the physiological hormone profile secreted by the human thyroid. Combining DTE with levothyroxine (L-T4) may overcome current therapeutic bottlenecks. First, L-T4 given in adequate doses provides the major T4-mediated TSH suppression, while the small amount of T3 supplied by DTE acts directly on pituitary thyrotrophs, bypassing impaired DIO2 conversion; this pharmacodynamic synergy yields tighter TSH control, steadier serum levels, and fewer thyrotoxic side-effects. Second, because thyroid-hormone receptor isoforms are differentially expressed across tissues and display distinct T4/T3 affinities, the combination allows finer tuning of thyroid hormone signaling-maintaining adequate tumor suppression while attenuating adverse cardiac and skeletal effects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of adequate TSH suppressionTime frame: 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment
- Time to TSH suppression targetTime frame: 1, 3, 6, 9, 12 months postoperative and 1 month after every dose adjustment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.